Phaseline

Targets › ACE

ACE (Angiotensin-converting enzyme): drug programs, companies and trials

18 programs from 17 companies in 18 trials: 8 Phase 4, 5 Phase 3, 5 Phase 2; Cardiovascular, Immunology, Oncology; next expected readout Dec 2026.

Dipeptidyl carboxypeptidase that removes dipeptides from the C-terminus of a variety of circulating hormones, such as angiotensin I, bradykinin or enkephalins, thereby playing a key role in the regulation of blood pressure, electrolyte homeostasis or synaptic plasticity. Composed of two similar catalytic domains, each possessing a functional active site, with different selectivity for substrates. (UniProt, P12821)

Open in Phaseline: the race on ACE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Martin HuelsmannEnalapril
Angiotensin-converting enzyme inhibitor
ACEPhase 4Heart DiseasesDec 2026
Cedars-Sinai Medical CenterLisinopril
Angiotensin-converting enzyme inhibitor
ACEPhase 4Coronary Artery DiseaseApr 2027
University of NebraskaRamipril
Angiotensin-converting enzyme inhibitor
ACEPhase 4Peripheral Arterial DiseaseJun 2027
Vastra Gotaland RegionRamipril
Angiotensin-converting enzyme inhibitor
ACEPhase 4Myocardial InfarctDec 2027
Nebraska Methodist Health SystemEnalapril
Angiotensin-converting enzyme inhibitor
ACEPhase 4Hypertension in PregnancyJul 2028
National Heart Centre SingaporeRenin-angiotensin-aldosterone system inhibitors (ACE inhibitors, Angiotensin II
ACE inhibition and angiotensin II receptor antagonism
ACE, AGTR1Phase 4Diabetes MellitusJun 2034
Evi Liliek WulandariRamipril
Angiotensin-converting enzyme inhibitor
ACEPhase 4Chronic Kidney Disease–
Fundación EPICRamipril
Angiotensin-converting enzyme inhibitor
ACEPhase 4Coronary Artery Disease–
Women and Infants Hospital of Rhode IslandEnalapril
Angiotensin-converting enzyme inhibitor
ACEPhase 3PreeclampsiaOct 2027
Sherief Abd-ElsalamRamipril
Angiotensin-converting enzyme inhibitor
ACEPhase 3Liver FibrosesNov 2027
Northern California Institute of Research and EducationPolycap
Fixed-dose combination: aspirin (antiplatelet), simvastatin (HMG-CoA reductase inhibitor),
HMGCR, ACEPhase 3StrokeJan 2029
Ain Shams UniversityCaptopril
Angiotensin-converting enzyme inhibitor
ACEPhase 3Cardiotoxicity–
HaEmek Medical Center, IsraelRamipril
Angiotensin-converting enzyme inhibitor
ACEPhase 3Persistent Developmental Stuttering–
UNC Lineberger Comprehensive Cancer CenterLisinopril
Angiotensin-converting enzyme inhibitor
ACEPhase 2Chest Wall TumorFeb 2029
Oslo University HospitalEnalapril
Angiotensin-converting enzyme inhibitor
ACEPhase 2Venous MalformationDec 2029
Northwell HealthBenazepril
ACE inhibitor
ACEPhase 2Systemic Lupus Erythematosus–
Northwell HealthLisinopril
Angiotensin-converting enzyme inhibitor
ACEPhase 2Systemic Lupus Erythematosus–
Northwestern UniversityLisinopril
Angiotensin-converting enzyme inhibitor
ACEPhase 2Hepatocellular Carcinoma–

Conditions

Coronary Artery Disease (2) Systemic Lupus Erythematosus (2) Chronic Kidney Disease (1) Persistent Developmental Stuttering (1) Cardiotoxicity (1) Stroke (1) Venous Malformation (1) Preeclampsia (1) Heart Diseases (1) Myocardial Infarct (1) Hypertension in Pregnancy (1) Peripheral Arterial Disease (1)

Modalities

small molecule (17), mixed (1)

Companies

Northwell Health (2) Evi Liliek Wulandari (1) Cedars-Sinai Medical Center (1) HaEmek Medical Center, Israel (1) Ain Shams University (1) Northern California Institute of Research and Education (1) Oslo University Hospital (1) Women and Infants Hospital of Rhode Island (1) Martin Huelsmann (1) Vastra Gotaland Region (1) Nebraska Methodist Health System (1) University of Nebraska (1) Sherief Abd-Elsalam (1) National Heart Centre Singapore (1) UNC Lineberger Comprehensive Cancer Center (1) Northwestern University (1) Fundación EPIC (1)

Related targets

HMGCR (1) AGTR1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.